Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Safety, Tolerability, and Proof-of-Concept Study of VGL101 in Patients With Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia (ALSP) (The Ignite Study)

NCT05677659 is registered in ClinicalTrials.gov with Vigil Neuroscience, Inc. as lead sponsor.

NCT NCT05677659
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05677659 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Safety, Tolerability, and Proof-of-Concept Study of VGL101 in Patients With Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia (ALSP) (The Ignite Study)
Lead sponsor
Vigil Neuroscience, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
December 14, 2022
Completion date
June 4, 2025
Enrollment
20 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

alsp